Decellularized bovine placentome for portacavally-interposed heterotopic liver transplantation in rats

Zurab Kakabadze, Lia Karalashvili, David Chakhunashvili, Necat Havlioglu, Merab Janelidze, Ann Kakabadze, Yogeshwar Sharma, Sanjeev Gupta

Research output: Contribution to journalArticle

Abstract

Scaffolds from healthy placentae offer advantages for tissue engineering with undamaged matrix, associated cytoprotective molecules, and embedded vessels for revascularization. As size disparities in human placenta and small recipients hamper preclinical studies, we studied alternative of bovine placentomes in smaller size ranges. Multiple cow placentomes were decellularized and anatomical integrity was analyzed. Tissue engineering used inbred donor rat livers. Placentomes were hepatized and immediately transplanted in rats with perfusion from portal vein and drainage into inferior vena cava. Cows yielded 99 ± 16 placentomes each. Of these, approximately 25% had 3 to 9 cm diameter and 7 to 63 ml volume, which was suitable for transplantation. After decellularization, angiography and casts documented 100% of vessels and vascular networks were well-perfused without disruptions or leaks. The residual matrix also remained intact for transplantation of placentomes. Perfusion in transplanted placentomes was maintained over up to 30 days. Liver tissue reassembled with restoration of hepatic acinar and sinusoidal structure. Transplanted tissue was intact without apoptosis, or necrosis. Hepatic functions were maintained. Preservation of hepatic homeostasis was verified by cytofluorimetric analysis of hepatocyte ploidy. The prevalence in healthy and transplanted liver of diploid, tetraploid and higher ploidy classes was similar with 57%, 41% and 2% versus 51%, 46.5% and 2.6%, respectively, p = 0.77, ANOVA. Conclusions: Cow placentomes will allow therapeutic development with disease models in small animals. This will also advance drug or toxicology studies. Portasystemic interposition of engineered liver will be particularly suitable for treating hepatic insufficiencies (metabolic, secretory or detoxification needs), including for children or smaller adults.

Original languageEnglish (US)
Pages (from-to)293-301
Number of pages9
JournalMaterials Science and Engineering C
Volume97
DOIs
StatePublished - Apr 1 2019

Fingerprint

transplantation
liver
Liver
rats
Rats
tissue engineering
Tissue engineering
vessels
toxicology
Tissue
homeostasis
Detoxification
Angiography
angiography
necrosis
apoptosis
Cell death
Scaffolds (biology)
matrices
Analysis of variance (ANOVA)

Keywords

  • Placenta
  • Portal hypertension
  • Regeneration
  • Transplantation
  • Vascular biology

ASJC Scopus subject areas

  • Materials Science(all)
  • Condensed Matter Physics
  • Mechanics of Materials
  • Mechanical Engineering

Cite this

Decellularized bovine placentome for portacavally-interposed heterotopic liver transplantation in rats. / Kakabadze, Zurab; Karalashvili, Lia; Chakhunashvili, David; Havlioglu, Necat; Janelidze, Merab; Kakabadze, Ann; Sharma, Yogeshwar; Gupta, Sanjeev.

In: Materials Science and Engineering C, Vol. 97, 01.04.2019, p. 293-301.

Research output: Contribution to journalArticle

Kakabadze, Z, Karalashvili, L, Chakhunashvili, D, Havlioglu, N, Janelidze, M, Kakabadze, A, Sharma, Y & Gupta, S 2019, 'Decellularized bovine placentome for portacavally-interposed heterotopic liver transplantation in rats', Materials Science and Engineering C, vol. 97, pp. 293-301. https://doi.org/10.1016/j.msec.2018.12.025
Kakabadze, Zurab ; Karalashvili, Lia ; Chakhunashvili, David ; Havlioglu, Necat ; Janelidze, Merab ; Kakabadze, Ann ; Sharma, Yogeshwar ; Gupta, Sanjeev. / Decellularized bovine placentome for portacavally-interposed heterotopic liver transplantation in rats. In: Materials Science and Engineering C. 2019 ; Vol. 97. pp. 293-301.
@article{10adf3f7d1924a80bf8a8f84167db23c,
title = "Decellularized bovine placentome for portacavally-interposed heterotopic liver transplantation in rats",
abstract = "Scaffolds from healthy placentae offer advantages for tissue engineering with undamaged matrix, associated cytoprotective molecules, and embedded vessels for revascularization. As size disparities in human placenta and small recipients hamper preclinical studies, we studied alternative of bovine placentomes in smaller size ranges. Multiple cow placentomes were decellularized and anatomical integrity was analyzed. Tissue engineering used inbred donor rat livers. Placentomes were hepatized and immediately transplanted in rats with perfusion from portal vein and drainage into inferior vena cava. Cows yielded 99 ± 16 placentomes each. Of these, approximately 25{\%} had 3 to 9 cm diameter and 7 to 63 ml volume, which was suitable for transplantation. After decellularization, angiography and casts documented 100{\%} of vessels and vascular networks were well-perfused without disruptions or leaks. The residual matrix also remained intact for transplantation of placentomes. Perfusion in transplanted placentomes was maintained over up to 30 days. Liver tissue reassembled with restoration of hepatic acinar and sinusoidal structure. Transplanted tissue was intact without apoptosis, or necrosis. Hepatic functions were maintained. Preservation of hepatic homeostasis was verified by cytofluorimetric analysis of hepatocyte ploidy. The prevalence in healthy and transplanted liver of diploid, tetraploid and higher ploidy classes was similar with 57{\%}, 41{\%} and 2{\%} versus 51{\%}, 46.5{\%} and 2.6{\%}, respectively, p = 0.77, ANOVA. Conclusions: Cow placentomes will allow therapeutic development with disease models in small animals. This will also advance drug or toxicology studies. Portasystemic interposition of engineered liver will be particularly suitable for treating hepatic insufficiencies (metabolic, secretory or detoxification needs), including for children or smaller adults.",
keywords = "Placenta, Portal hypertension, Regeneration, Transplantation, Vascular biology",
author = "Zurab Kakabadze and Lia Karalashvili and David Chakhunashvili and Necat Havlioglu and Merab Janelidze and Ann Kakabadze and Yogeshwar Sharma and Sanjeev Gupta",
year = "2019",
month = "4",
day = "1",
doi = "10.1016/j.msec.2018.12.025",
language = "English (US)",
volume = "97",
pages = "293--301",
journal = "Materials Science and Engineering C",
issn = "0928-4931",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Decellularized bovine placentome for portacavally-interposed heterotopic liver transplantation in rats

AU - Kakabadze, Zurab

AU - Karalashvili, Lia

AU - Chakhunashvili, David

AU - Havlioglu, Necat

AU - Janelidze, Merab

AU - Kakabadze, Ann

AU - Sharma, Yogeshwar

AU - Gupta, Sanjeev

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Scaffolds from healthy placentae offer advantages for tissue engineering with undamaged matrix, associated cytoprotective molecules, and embedded vessels for revascularization. As size disparities in human placenta and small recipients hamper preclinical studies, we studied alternative of bovine placentomes in smaller size ranges. Multiple cow placentomes were decellularized and anatomical integrity was analyzed. Tissue engineering used inbred donor rat livers. Placentomes were hepatized and immediately transplanted in rats with perfusion from portal vein and drainage into inferior vena cava. Cows yielded 99 ± 16 placentomes each. Of these, approximately 25% had 3 to 9 cm diameter and 7 to 63 ml volume, which was suitable for transplantation. After decellularization, angiography and casts documented 100% of vessels and vascular networks were well-perfused without disruptions or leaks. The residual matrix also remained intact for transplantation of placentomes. Perfusion in transplanted placentomes was maintained over up to 30 days. Liver tissue reassembled with restoration of hepatic acinar and sinusoidal structure. Transplanted tissue was intact without apoptosis, or necrosis. Hepatic functions were maintained. Preservation of hepatic homeostasis was verified by cytofluorimetric analysis of hepatocyte ploidy. The prevalence in healthy and transplanted liver of diploid, tetraploid and higher ploidy classes was similar with 57%, 41% and 2% versus 51%, 46.5% and 2.6%, respectively, p = 0.77, ANOVA. Conclusions: Cow placentomes will allow therapeutic development with disease models in small animals. This will also advance drug or toxicology studies. Portasystemic interposition of engineered liver will be particularly suitable for treating hepatic insufficiencies (metabolic, secretory or detoxification needs), including for children or smaller adults.

AB - Scaffolds from healthy placentae offer advantages for tissue engineering with undamaged matrix, associated cytoprotective molecules, and embedded vessels for revascularization. As size disparities in human placenta and small recipients hamper preclinical studies, we studied alternative of bovine placentomes in smaller size ranges. Multiple cow placentomes were decellularized and anatomical integrity was analyzed. Tissue engineering used inbred donor rat livers. Placentomes were hepatized and immediately transplanted in rats with perfusion from portal vein and drainage into inferior vena cava. Cows yielded 99 ± 16 placentomes each. Of these, approximately 25% had 3 to 9 cm diameter and 7 to 63 ml volume, which was suitable for transplantation. After decellularization, angiography and casts documented 100% of vessels and vascular networks were well-perfused without disruptions or leaks. The residual matrix also remained intact for transplantation of placentomes. Perfusion in transplanted placentomes was maintained over up to 30 days. Liver tissue reassembled with restoration of hepatic acinar and sinusoidal structure. Transplanted tissue was intact without apoptosis, or necrosis. Hepatic functions were maintained. Preservation of hepatic homeostasis was verified by cytofluorimetric analysis of hepatocyte ploidy. The prevalence in healthy and transplanted liver of diploid, tetraploid and higher ploidy classes was similar with 57%, 41% and 2% versus 51%, 46.5% and 2.6%, respectively, p = 0.77, ANOVA. Conclusions: Cow placentomes will allow therapeutic development with disease models in small animals. This will also advance drug or toxicology studies. Portasystemic interposition of engineered liver will be particularly suitable for treating hepatic insufficiencies (metabolic, secretory or detoxification needs), including for children or smaller adults.

KW - Placenta

KW - Portal hypertension

KW - Regeneration

KW - Transplantation

KW - Vascular biology

UR - http://www.scopus.com/inward/record.url?scp=85058512670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058512670&partnerID=8YFLogxK

U2 - 10.1016/j.msec.2018.12.025

DO - 10.1016/j.msec.2018.12.025

M3 - Article

VL - 97

SP - 293

EP - 301

JO - Materials Science and Engineering C

JF - Materials Science and Engineering C

SN - 0928-4931

ER -